Navigation Links
Bionovo Announces 2007 Financial Results and Highlights
Date:3/13/2008

- Company Outlines Milestones for 2008 -

EMERYVILLE, Calif., March 13 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI) today announced financial results for the fourth quarter and full year ended December 31, 2007.

Fourth Quarter Results

The company reported revenues for the three months ended December 31, 2007 of $330,875 compared to $3,750 for the same period in 2006. The increase in revenues over the comparable period in 2006, is due primarily to the recognition of $239,625 from our National Institute of Health grant drawdown earned in 2007 and the recognition of unamortized deferred revenue of $91,250 as a result of the termination of our licensing agreement with United Biotechnology Corporation ("UBC") of Taiwan on October 15, 2007.

Total operating expenses for the three months ended December 31, 2007 were $4.3 million compared to $2.0 million for the same period in 2006.

The company reported a net loss for the three months ended December 31, 2007 of $3.7 million, or $0.05 per share, compared with a net loss of $1.9 million, or $0.04 per share, for the same period in 2006.

Full Year Results

For the year ended December 31, 2007 total revenues were $581,750 compared with $15,000 for the same period in 2006. Revenues in 2007 also included a National Institute of Health (NIH) grant drawdown of $239,625 received for 2006 and the recognition of $11,250 in amortization from the proceeds of our licensing and technology transfer agreement with UBC of Taiwan

For the year ended December 31, 2007 total operating expenses were $14.2 million compared with $5.8 million for the same period in 2006. The increase in 2007 operating expenses include the impact of research and development expense for the development of our lead drug candidates, clinical trial expenses and a related increase in operational support.

The net loss for the year ended December 31, 2007 was $12.9 million, or $0.20 per share, compared with a net loss of $5.6 million, or $0.11 per share, for the same period in 2006. The year-over-year increase in net loss was driven primarily by the increased activity related to our clinical trials and a related increase in operational support.

As of December 31, 2007, cash, cash equivalents and short-term investments totaled approximately $33.3 million compared to $3.1 million at December 31, 2006. The increase in cash, cash equivalents and short term investments in 2007 is due primarily to $14.5 million, net of financing expense, raised from our Private Placement (a.k.a. "PIPE") completed in January 2007, a public offering completed in October 2007, which raised aggregate net cash proceeds of $24.0 million, and $4.8 million received from the exercise of stock options and warrants, offset by net cash used in operating activities of $10.3 million.

2007 Highlights and 2008 Plans

MF101

* Clinical Trials -- In addition to starting a pharmacokinetics trial

of its lead menopause drug candidate, MF101, early in the year,

Bionovo also announced results from the Phase 2 trial.

-- In June 2007, Bionovo reported on a trial in which 217 severe

menopausal women were treated and showed positive results with

respect to safety, tolerability and efficacy. This trial

successfully met its objectives, and will now allow the company

to move forward in developing this safe and efficacious

treatment for an indication that is poorly served by the

current pharmaceutical offerings.

-- Data from this Phase 2 trial was presented and deemed the top

scoring abstract at the North American Menopause Society's

annual meeting. The abstract, entitled, "A Novel Selective

Estrogen Receptor-Beta Agonist for the Treatment of Menopausal

Hot Flushes," was presented by the company's principal

investigator, Dr. Deborah Grady, a world leading expert on

menopause. The abstract was also published in the journal,

Menopause.

* Bionovo described a new class of therapeutic compounds. A paper was

published in the journal, Molecular and Cellular Endocrinology,

covering the isolation, identification and description of a chemical

compound, liquiritigenin (an active ingredient in Bionovo's drug

candidate, MF101), which represents the new class of therapeutic

compounds showing promise for the safe, effective treatment of

menopausal symptoms such as hot flashes. This is an important

milestone in the development and protection of our intellectual

property.

* During 2008, we expect to review the Phase 2 study results and Phase

3 proposal with the FDA, and to initiate the Phase 3 study by the

end of the third quarter.

BZL101

* Bionovo presented the mechanism of action data behind its

anti-cancer agent, BZL101, currently undergoing Phase 1/2 clinical

testing for late stage breast cancer, at the American Association of

Cancer Research (AACR). The presentation described how BZL101

elicits its cytotoxic activity on cancer cells while avoiding normal

cells.

* Bionovo began enrolling patients into a Phase 1/2 clinical trial of

BZL101 for the treatment of advanced breast cancer, after presenting

positive Phase 1 findings of BZL101 at the American Association of

Cancer Research.

* During 2008, we expect to continue the Phase 2 study being conducted

in centers around the U.S. We also expect to discuss the drug

candidate's mechanism of action in more detail, as well as to report

progress of the on-going trial at major scientific conferences.

VG101

* During 2008, we expect to receive an IND and commence a Phase 1/2

trial of VG101, our drug candidate for the treatment of menopausal

vaginal dryness.

Financing

* During 2007, Bionovo closed a $15.7 million private placement. Later

in the year the company began trading on the NASDAQ Capital Market.

In October 2007, Bionovo completed a successful public follow-on

offering, from which net proceeds to the company were approximately

$24 million.

"We believe our achievements in the last year have positioned Bionovo well for an exciting and promising 2008," said Isaac Cohen, O.M.D., Bionovo's chairman and CEO. "With the proceeds of our recent public offering, we are in a strong financial position to support the ongoing product development and clinical trials for our lead product candidates for metastatic breast cancer, BZL101, and menopausal hot flashes, MF101. We are also pleased with the interest we have received from potential partners in ongoing discussions of our programs and drug candidates. With the combination of our strong financial position, our partner discussions, and the momentum in our clinical trials we believe we are on the right path to become a leader in the areas of breast cancer and women's health."

About Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit: http://www.bionovo.com.

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.

Bionovo, Inc.

(A Development Stage Company)

Condensed Statements of Operations

Accumulated

from

February 1,

2002

Three Three Twelve Twelve (Date of

months months months months inception)

ended ended ended ended To

December December December December December

31, 31, 31, 31, 31,

2007 2006 2007 2006 2007

Revenues $330,875 $3,750 $581,750 $15,000 $659,490

Operating

expenses:

Research

and

devel-

opment 2,725,299 1,403,550 9,937,743 4,021,149 15,792,205

General

and

administ-

rative 1,550,431 493,124 4,126,078 1,488,225 6,909,101

Sales and

marketing 43,889 77,924 157,489 310,941 542,666

Merger cost - - - - 1,964,065

Total

operating

expenses 4,319,619 1,974,598 14,221,310 5,820,315 25,208,037

Loss from

opera-

tions (3,988,744) (1,970,848) (13,639,560) (5,805,315) (24,548,547)

Change in

fair value

of warrant

liability - - - - 831,288

Interest

income 139,987 71,860 657,944 261,515 1,068,416

Interest

expense (17,685) (15,928) (86,582) (47,354) (237,017)

Other

income

(expense) 175,842 (23,450) 170,602 (23,446) 144,897

Income

(loss)

before

income

tax (3,690,600) (1,938,362) (12,897,596) (5,614,600) (22,740,963)

Income

tax

provision (1,002) (800) (3,402) (3,200) (9,002)

Net

loss $(3,691,602) $(1,939,162) $(12,900,998) $(5,617,800) $(22,749,965)

Basic

and

diluted

net loss

per common

share $(0.05) $(0.04) $(0.20) $(0.11) $(0.63)

Shares used

in computing

basic and

diluted net

loss per

common

share 72,867,303 51,276,537 65,762,764 49,923,115 36,294,284

Bionovo, Inc.

(A Development Stage Company)

Consolidated Balance Sheet

December 31, December 31,

2007 2006

ASSETS

Current assets:

Cash and cash equivalents $28,472,485 $2,571,439

Short-term investments 4,823,938 484,017

Receivables from officers and employees 285,899 1,796

Prepaid expenses and other current assets 405,381 183,528

Total current assets 33,987,703 3,240,780

Property and equipment, net 3,900,248 1,672,904

Other assets and patent pending, net 277,220 58,613

Total assets $38,165,171 $4,972,297

LIABILITIES AND SHAREHOLDERS' EQUITY

Current liabilities:

Accounts payable $299,677 $546,909

Accrued clinical costs 298559 -

Accrued compensation and benefits 462,485 114,392

Current portion of lease obligation 706,710 292,333

Deferred revenue - 15,000

Other current liabilities 949,200 119,092

Total current liabilities 2,716,631 1,087,726

Non-current portion of lease obligation 526,346 300,741

Non-current portion of deferred revenue - 87,500

Commitments and contingencies

Shareholders' equity:

Common stock, $0.0001 par value, 190,000,000

shares authorized; issued and outstanding shares:

66,036,435 at December 31, 2007; 51,337,224

at December 31, 2006. 8,166 5,134

Additional paid-in capital 57,659,513 13,340,163

Accumulated other comprehensive income 4,480 -

Accumulated deficit (22,749,965) (9,848,967)

Total shareholders' equity 34,922,194 3,496,330

Total liabilities and shareholders' equity $38,165,171 $4,972,297

* The balance sheets at December 31, 2007 and 2006 has been derived from

the audited financial statements at that date but does not include all

of the information and footnotes required by accounting principles

generally accepted in the United States for complete financial


'/>"/>
SOURCE Bionovo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Bionovo Announces Closing of Public Offering of Common Stock
2. Bionovo Describes a New Class of Therapeutic Compounds
3. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
4. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
5. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
6. HEI, Inc. Announces Sale of RFID Division Assets
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
8. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
9. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
10. Brooke Franchise Corporation Announces Selected July Results
11. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media with ... X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color ... users can now reveal the media of their split screens with growing colorful ...
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star ... , Millions of individuals in the United States and Canada wear eyeglasses. Once considered ... both correct vision and make a fashion statement. Even celebrities use glasses as a ...
(Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
(Date:6/25/2016)... ... 2016 , ... Austin residents seeking Mohs surgery services, can now turn to ... Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to ... fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of ...
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Bracket , a leading clinical trial technology ... outcomes platform, Bracket eCOA (SM) 6.0, at the 52 ... 30, 2016 in Philadelphia , Pennsylvania.  A ... product of its kind to fully integrate with RTSM, will ... 6.0 is a flexible platform for electronic clinical outcomes assessments ...
(Date:6/23/2016)... , June 23, 2016 ... Oticon , industry leaders in advanced ... launch of Oticon Opn ™, the world,s first ... of possibilities for IoT devices.      (Photo: ... Oticon introduces a number of ,world firsts,: ...
(Date:6/23/2016)... 2016  Experian Health, the healthcare industry ... patient payment and care experience, today announced ... and services that will enhance the breadth ... These award-winning solutions will enable healthcare professionals ... in an ever-changing environment and redefine front-office ...
Breaking Medicine Technology: